FDA
-
-
-
-
-
-
-
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Collaboration with Neurocrine (NBIX) Biosciences Achieves $15M Regulatory Milestone
-
-
-
-
-
-
-
Xenon Pharmaceuticals (XENE) Reports Additional Positive Data from Phase 2b ‘X-TOLE’ Trial
-
-
-
-
-
-
-
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
-
-
-
-
-
-
-
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
-
251,865 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All